Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 333 versus vosoritide in children with achondroplasia
2025-523811-12-00Phase 3Authorised
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 13
01
Overview
Phase 3, randomised trial in achondroplasia (ACH) comparing BMN 333 with Voxzogo (2 arms). Primary endpoints: Predicted annualized growth velocity at Week 52 and Annualized growth velocity at Week 52. Planned start Jul 2026; status: authorised.
02
Drugs
BMN 333vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2025-523811-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523811-12-00.